Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACETNASDAQ:APGNNASDAQ:ITRMNASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.63-6.0%$0.67$0.45▼$1.70$55.42M1.67710,979 shs532,728 shsAPGNApexigen$0.39$0.39$0.33▼$8.28$9.57M3.6967,731 shsN/AITRMIterum Therapeutics$0.94-4.6%$1.03$0.81▼$3.02$39.60M2.791.05 million shs560,999 shsPRLDPrelude Therapeutics$0.84-2.4%$0.90$0.61▼$6.80$48.58M1.25281,936 shs69,982 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio0.00%-10.70%-3.40%-26.72%-51.09%APGNApexigen0.00%0.00%0.00%0.00%0.00%ITRMIterum Therapeutics0.00%-0.09%+6.25%-30.77%-20.16%PRLDPrelude Therapeutics0.00%-10.37%-2.90%+19.51%-77.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACETAdicet Bio1.9011 of 5 stars3.32.00.00.01.41.70.6APGNApexigenN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.8581 of 5 stars3.55.00.00.00.60.00.0PRLDPrelude Therapeutics3.223 of 5 stars3.52.00.00.00.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio 2.60Moderate Buy$7.501,090.48% UpsideAPGNApexigen 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00852.78% UpsidePRLDPrelude Therapeutics 3.00Buy$4.50435.71% UpsideCurrent Analyst Ratings BreakdownLatest APGN, ITRM, ACET, and PRLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.005/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M2.09N/AN/A$2.26 per share0.28APGNApexigenN/AN/AN/AN/A($0.09) per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/APRLDPrelude Therapeutics$7M6.78N/AN/A$2.39 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$117.12M-$1.30N/AN/AN/AN/A-59.05%-50.66%8/12/2025 (Estimated)APGNApexigen-$32.07MN/A0.00∞N/AN/A-614.82%-133.30%N/AITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)PRLDPrelude Therapeutics-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)Latest APGN, ITRM, ACET, and PRLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/6/2025Q1 2025ACETAdicet Bio-$0.34-$0.31+$0.03-$0.31N/AN/A5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet BioN/AN/AN/AN/AN/AAPGNApexigenN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A9.349.34APGNApexigenN/A0.820.82ITRMIterum TherapeuticsN/A3.723.58PRLDPrelude TherapeuticsN/A5.185.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%APGNApexigen13.65%ITRMIterum Therapeutics9.21%PRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio7.80%APGNApexigen19.20%ITRMIterum Therapeutics9.20%PRLDPrelude Therapeutics63.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio9082.71 million76.26 millionOptionableAPGNApexigen1124.86 million20.09 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionablePRLDPrelude Therapeutics12056.46 million20.38 millionOptionableAPGN, ITRM, ACET, and PRLD HeadlinesRecent News About These CompaniesPrelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLCJune 8, 2025 | marketbeat.comPrelude Therapeutics to Present at Major Healthcare Conferences in June 2025June 3, 2025 | msn.comPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesJune 2, 2025 | globenewswire.comPrelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challengesMay 28, 2025 | investing.comPathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drugMay 15, 2025 | fiercebiotech.comPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comPrelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025May 5, 2025 | msn.comPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comPrelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer TherapiesApril 30, 2025 | msn.comPrelude Announces Presentations at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comPrelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should KnowApril 10, 2025 | zacks.comPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in StockMarch 28, 2025 | insidertrades.comPrelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 SharesMarch 15, 2025 | insidertrades.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)March 12, 2025 | markets.businessinsider.comPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)March 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPGN, ITRM, ACET, and PRLD Company DescriptionsAdicet Bio NASDAQ:ACET$0.63 -0.04 (-5.97%) Closing price 04:00 PM EasternExtended Trading$0.64 +0.02 (+2.38%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Apexigen NASDAQ:APGNApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Iterum Therapeutics NASDAQ:ITRM$0.94 -0.05 (-4.59%) Closing price 04:00 PM EasternExtended Trading$0.94 +0.00 (+0.04%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Prelude Therapeutics NASDAQ:PRLD$0.84 -0.02 (-2.38%) Closing price 04:00 PM EasternExtended Trading$0.84 0.00 (-0.48%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
